BeiGene commences Phase I trial of BGB-A317 in China to treat solid tumours

Clinical-stage biopharmaceutical company BeiGene has commenced its Phase I clinical trial of BGB-A317 in China to treat advanced solid tumours.

Source: Drug Development Technology - January 3, 2017 Category: Pharmaceuticals Source Type: news